Clinical trials: Glioma, Malignant
Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
RATIONALE: Genetically-modified neural stem cells (NSCs) that convert 5-fluorocytosine (5-FC) into the chemotherapy agent 5-FU (fluorouracil) at sites of tumor in the brain may be an effective treatment for glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma, Recurrent Grade IV Glioma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT01172964
- Testing
- flucytosine, polymerase chain reaction, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Malignant Glioma, Glioblastoma Multiforme
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL13-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
- Trial name
- NCT00041587
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- INSYS Therapeutics Inc
Brain and Central Nervous System Tumors, Leukemia
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00458744
- Testing
- talotrexin, chemotherapy
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors
Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00357253
- Testing
- capecitabine, radiation therapy
- Where
- 12 sites in United States
- Volunteers
- 24 people
- Sponsor
- Pediatric Brain Tumor Consortium
Malignant Glioma, Life Experiences
Treatment Decision-making in Patients With Recurrent High-grade Glioma
This qualitative study explores the lived experience of high-grade glioma patients and their close relatives at time of recurrence. With focus on the decision-making about treatment and care..
- Trial name
- NCT04013828
- Where
- 2 sites in Denmark
- Volunteers
- 29 people
- Sponsor
- Odense University Hospital
High Grade Glioma, Astrocytoma, Grade III
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
This is a Phase 2 study of newly diagnosed patients with high grade glioma (HGG) undergoing standard radiation therapy and temozolomide treatment.
- Conditions
- High Grade Glioma, Astrocytoma, Grade III, Glioblastoma
- Trial name
- BMX-HGG (NCT02655601)
- Testing
- BMX-001, Radiation Therapy, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 177 people
- Sponsor
- BioMimetix JV, LLC
Glioblastoma, Glioma
Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
This phase I trial studies the side effects and best dose of ascorbic acid when given together with bevacizumab in treating patients with high grade glioma that has come back (recurrent).
- Trial name
- NCT02833701
- Testing
- Ascorbic Acid, Bevacizumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Nebraska
Brain and Central Nervous System Tumors, Lymphoma
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00004212
- Testing
- filgrastim, exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
5-aminolevulinic Acid, Malignant Glioma of Brain
Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA）
This trial is an open-label, multicenter, phase III clinical study，conducted in patients with newly diagnosed or recurrent malignant high-grade (WHO grades 3~4) glioma, to evaluate the efficacy and safety of a single oral dose of…
- Trial name
- NCT06417281
- Testing
- 5 Aminolevulinic Acid
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Glioblastoma Multiforme, Glioblastoma
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
Glioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, GBM
- Trial name
- NCT02663271
- Testing
- Bevacizumab, Optune, Brain MRI
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Glioma, Glioblastoma
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
Background: Gliomas are the most common malignant brain tumors. Some have certain changes (mutations) in the genes isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2).
- Conditions
- Glioma, Glioblastoma, High Grade Glioma, Low Grade Glioma
- Trial name
- NCT03718767
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Glioma, High Grade Meningioma
Liquid Biopsy in High-grade Gliomas and Meningiomas
The general objective of this project is to evaluate the value of cell-free DNA circulating in plasma as a marker of tumor evolution in patients with high-grade gliomas and meningiomas.
- Trial name
- SOPRANO (NCT05630664)
- Where
- 5 sites in Italy
- Volunteers
- 90 people
- Sponsor
- IRCCS San Raffaele
High Grade Glioma, Brain Cancer
Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas
Immune checkpoint blockade therapies targeting the immunomodulatory effect of cytotoxic T-lymphocyte antigen (CTLA-4) and programmed cell death-1/ Programmed death-ligand 1 (PD-1/PD-L1) have recently demonstrated survival benefit…
- Trial name
- REVOLUMAB (NCT03925246)
- Testing
- Nivolumab
- Where
- 7 sites in France
- Volunteers
- 43 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma)
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of avutometinib and defactinib and to determine the preliminary antitumour activity of avutometinib and defactinib administered at the recommended…
- Conditions
- Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
- Trial name
- 5G-RUBY (NCT06630260)
- Testing
- Avutometinib, Defactinib, Temozolomide
- Where
- 3 sites in United Kingdom
- Volunteers
- 182 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Glioma, Glioblastoma
ANG1005 in Patients With Recurrent High-Grade Glioma
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics…
- Conditions
- Glioma, Glioblastoma, Brain Tumor, Recurrent
- Trial name
- NCT01967810
- Testing
- ANG1005, Bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 73 people
- Sponsor
- Angiochem Inc
Glioma, Glioblastoma
A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
The purpose of this study is to find out about the safety of adding the investigational drug motexafin gadolinium to a standard course of chemotherapy with temozolomide for patients with malignant glioma.
- Conditions
- Glioma, Glioblastoma, Astrocytoma, Oligodendroglioma
- Trial name
- NCT00080054
- Testing
- Motexafin Gadolinium Injection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Pharmacyclics LLC.
Glioblastoma, Gliosarcoma
Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas
This is a single-center, open-label, non-randomized, Phase I/IIa study to investigate the safety, tolerability, and antitumor efficacy of AXL1717 (picropodophyllin as active agent formulated in an oral suspension; PPP) in…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- AXL1717 (NCT01721577)
- Testing
- AXL1717
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rush University Medical Center
High-grade Glioma, WHO Grade Ⅳ Glioma
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4…
- Trial name
- NCT06482905
- Testing
- Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
- Where
- 4 sites in United States, China
- Volunteers
- 52 people
- Sponsor
- Tcelltech Inc.
Glioma
Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
Gliomas are the most common type of primary brain tumors, with the main treatment modalities including surgery, radiotherapy, and chemotherapy.
- Trial name
- NCT06818331
- Testing
- SMES+PTX, Paclitaxel, Specific mode electroacupuncture stimulation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Third Affiliated hospital of Zhejiang Chinese Medical University
Malignant Neoplasms of Brain
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells.
- Trial name
- ATTAC (NCT00639639)
- Testing
- tetanus toxoid, therapeutic autologous dendritic cells, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Gary Archer Ph.D.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.